#Denmark #Lundbeck #Valby #Vyepti #Rexulti

Lundbeck's Strong Performance in H1 2026

In an impressive financial showing, Lundbeck has reported a remarkable 16% increase in total revenue for the first half of 2026. The company's financial results reveal a total revenue of DKK 13,588 million, underscoring their solid commercial strategies. The significant growth reflects not only the robust performance of its key products, Vyepti® and Rexulti®, but also the successful transition to a partnership model in 27 markets, which is advancing as planned.

Financial Overview

For the United States market, Lundbeck reported a staggering revenue of DKK 7,227 million, marking a 20% growth on a constant exchange rate (CER) basis. Europe contributed DKK 3,269 million, reflecting a healthy 14% growth (CER) as well. Meanwhile, international operations showed growth of 6% (CER), with revenue reaching DKK 2,792 million.

The company attributes this strong financial performance to its strategic brands, which saw a significant 17% increase in revenue, achieving DKK 10,463 million. This segment constituted an impressive 77% of the company’s total revenue. Among the standout performers:

• - Vyepti®: DKK 2,865 million (+46% CER)
• - Rexulti®: DKK 3,297 million (+17% CER)
• - Brintellix®/Trintellix®: DKK 2,331 million (Stable)
• - Abilify LAI Franchise: DKK 1,970 million (+7% CER)

Despite the successes, Lundbeck faced increased costs related to sales and R&D as it advanced its key pipeline assets. The adjusted EBITDA grew to DKK 4,765 million, an increase of 19% on a CER basis. Notably, EPS reached DKK 2.83, a significant 36% increase, supported by improved operational performance and streamlined financial expenses.

Management Insights

Charl van Zyl, President and CEO of Lundbeck, expressed satisfaction with the company’s performance, emphasizing the predominance of Vyepti® in driving growth. Van Zyl stated, "We delivered strong commercial performance in the first half of 2026, driven primarily by continued momentum for Vyepti®. Our pipeline continues to advance meaningfully, including the completion of enrollment in the DEEp OCEAN trial of bexicaserin."

The successful transition to a partnership model is expected to bolster future operations and market reach. Lundbeck's strategy appears clear as it approaches the upcoming phases of growth with confidence and a robust balance sheet.

Recent Developments

Several key developments have occurred within the company that demonstrate Lundbeck's commitment to innovation:

• - The U.S. FDA granted Fast Track designation to Lu AH69593, an investigational oral compound for sleep-wake disorders. This compound is currently in phase Ib trials for narcolepsy treatment.
• - The last patient of the DEEp OCEAN trial for bexicaserin, intended for developmental and epileptic encephalopathies, has been randomized, paving the way for promising results.
• - The appointment of Tarek Samad as Executive Vice President of Research and Development signals Lundbeck's focus on strengthening its leadership as it navigates through the complex pharmaceutical landscape.
• - Lundbeck has announced critical preclinical and clinical data presentations at various international congresses, which hint at the potential of their pipeline products in treating conditions like migraine and Cushing's disease.

The Road Ahead

Looking ahead, Lundbeck seems poised for sustained growth as it enhances its product portfolio and continues to innovate through strategic partnerships and R&D investments. The company’s current trajectory suggests a thriving future built upon its strong foundations in the pharmaceutical industry. This financial year already appears promising, with Lundbeck eagerly set to leverage its successes into broader market expansions and advancements in mental health treatment solutions.